ID   IGF1R_HUMAN             Reviewed;        1367 AA.
AC   P08069; B1B5Y2; Q14CV2; Q9UCC0;
DT   01-AUG-1988, integrated into UniProtKB/Swiss-Prot.
DT   01-AUG-1988, sequence version 1.
DT   10-MAY-2017, entry version 205.
DE   RecName: Full=Insulin-like growth factor 1 receptor;
DE            EC=2.7.10.1;
DE   AltName: Full=Insulin-like growth factor I receptor;
DE            Short=IGF-I receptor;
DE   AltName: CD_antigen=CD221;
DE   Contains:
DE     RecName: Full=Insulin-like growth factor 1 receptor alpha chain;
DE   Contains:
DE     RecName: Full=Insulin-like growth factor 1 receptor beta chain;
DE   Flags: Precursor;
GN   Name=IGF1R;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND PROTEIN SEQUENCE OF 31-56; 446-453;
RP   503-524; 561-579; 668-672 AND 721-729.
RC   TISSUE=Placenta;
RX   PubMed=2877871;
RA   Ullrich A., Gray A., Tam A.W., Yang-Feng T., Tsubokawa M., Collins C.,
RA   Henzel W., Bon T.L., Kathuria S., Chen E., Jacobs S., Francke U.,
RA   Ramachandran J., Fujita-Yamaguchi Y.;
RT   "Insulin-like growth factor I receptor primary structure: comparison
RT   with insulin receptor suggests structural determinants that define
RT   functional specificity.";
RL   EMBO J. 5:2503-2512(1986).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=1316909;
RA   Abbot A.M., Bueno R., Pedrini M.T., Murray J.M., Smith R.J.;
RT   "Insulin-like growth factor I receptor gene structure.";
RL   J. Biol. Chem. 267:10759-10763(1992).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Fetal brain;
RA   Nagase T., Kikuno R.F., Yamakawa H., Ohara O.;
RL   Submitted (FEB-2008) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS MET-388 AND HIS-605.
RG   NIEHS SNPs program;
RL   Submitted (JUN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16572171; DOI=10.1038/nature04601;
RA   Zody M.C., Garber M., Sharpe T., Young S.K., Rowen L., O'Neill K.,
RA   Whittaker C.A., Kamal M., Chang J.L., Cuomo C.A., Dewar K.,
RA   FitzGerald M.G., Kodira C.D., Madan A., Qin S., Yang X., Abbasi N.,
RA   Abouelleil A., Arachchi H.M., Baradarani L., Birditt B., Bloom S.,
RA   Bloom T., Borowsky M.L., Burke J., Butler J., Cook A., DeArellano K.,
RA   DeCaprio D., Dorris L. III, Dors M., Eichler E.E., Engels R.,
RA   Fahey J., Fleetwood P., Friedman C., Gearin G., Hall J.L., Hensley G.,
RA   Johnson E., Jones C., Kamat A., Kaur A., Locke D.P., Madan A.,
RA   Munson G., Jaffe D.B., Lui A., Macdonald P., Mauceli E., Naylor J.W.,
RA   Nesbitt R., Nicol R., O'Leary S.B., Ratcliffe A., Rounsley S., She X.,
RA   Sneddon K.M.B., Stewart S., Sougnez C., Stone S.M., Topham K.,
RA   Vincent D., Wang S., Zimmer A.R., Birren B.W., Hood L., Lander E.S.,
RA   Nusbaum C.;
RT   "Analysis of the DNA sequence and duplication history of human
RT   chromosome 15.";
RL   Nature 440:671-675(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-31.
RX   PubMed=1711844; DOI=10.1016/0006-291X(91)90654-P;
RA   Cooke D.W., Bankert L.A., Roberts C.T. Jr., Leroith D., Casella S.J.;
RT   "Analysis of the human type I insulin-like growth factor receptor
RT   promoter region.";
RL   Biochem. Biophys. Res. Commun. 177:1113-1120(1991).
RN   [8]
RP   PROTEIN SEQUENCE OF 31-45 AND 741-750, FUNCTION, AND FORMATION OF A
RP   HYBRID RECEPTOR WITH INSR.
RC   TISSUE=Placenta;
RX   PubMed=8257688; DOI=10.1021/bi00212a019;
RA   Kasuya J., Paz I.B., Maddux B.A., Goldfine I.D., Hefta S.A.,
RA   Fujita-Yamaguchi Y.;
RT   "Characterization of human placental insulin-like growth factor-
RT   I/insulin hybrid receptors by protein microsequencing and
RT   purification.";
RL   Biochemistry 32:13531-13536(1993).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1137-1193, AND TISSUE SPECIFICITY.
RC   TISSUE=Melanocyte;
RX   PubMed=8247543;
RA   Lee S.-T., Strunk K.M., Spritz R.A.;
RT   "A survey of protein tyrosine kinase mRNAs expressed in normal human
RT   melanocytes.";
RL   Oncogene 8:3403-3410(1993).
RN   [10]
RP   FUNCTION, SUBUNIT, AND AUTOPHOSPHORYLATION.
RX   PubMed=1846292; DOI=10.1021/bi00215a008;
RA   Tollefsen S.E., Stoszek R.M., Thompson K.;
RT   "Interaction of the alpha beta dimers of the insulin-like growth
RT   factor I receptor is required for receptor autophosphorylation.";
RL   Biochemistry 30:48-54(1991).
RN   [11]
RP   FUNCTION, AND FORMATION OF A HYBRID RECEPTOR WITH INSR.
RX   PubMed=8452530; DOI=10.1042/bj2900419;
RA   Soos M.A., Field C.E., Siddle K.;
RT   "Purified hybrid insulin/insulin-like growth factor-I receptors bind
RT   insulin-like growth factor-I, but not insulin, with high affinity.";
RL   Biochem. J. 290:419-426(1993).
RN   [12]
RP   FUNCTION, CATALYTIC ACTIVITY, AND AUTOPHOSPHORYLATION.
RX   PubMed=7679099;
RA   Kato H., Faria T.N., Stannard B., Roberts C.T. Jr., LeRoith D.;
RT   "Role of tyrosine kinase activity in signal transduction by the
RT   insulin-like growth factor-I (IGF-I) receptor. Characterization of
RT   kinase-deficient IGF-I receptors and the action of an IGF-I-mimetic
RT   antibody (alpha IR-3).";
RL   J. Biol. Chem. 268:2655-2661(1993).
RN   [13]
RP   INTERACTION WITH IRS1; SHC1 AND PIK3R1, MUTAGENESIS OF TYR-980 AND
RP   LYS-1033, AND PHOSPHORYLATION AT TYR-980.
RX   PubMed=7541045; DOI=10.1074/jbc.270.26.15639;
RA   Craparo A., O'Neill T.J., Gustafson T.A.;
RT   "Non-SH2 domains within insulin receptor substrate-1 and SHC mediate
RT   their phosphotyrosine-dependent interaction with the NPEY motif of the
RT   insulin-like growth factor I receptor.";
RL   J. Biol. Chem. 270:15639-15643(1995).
RN   [14]
RP   FORMATION OF A HYBRID RECEPTOR WITH INSR, AND TISSUE SPECIFICITY.
RX   PubMed=9355755; DOI=10.1042/bj3270209;
RA   Bailyes E.M., Nave B.T., Soos M.A., Orr S.R., Hayward A.C., Siddle K.;
RT   "Insulin receptor/IGF-I receptor hybrids are widely distributed in
RT   mammalian tissues: quantification of individual receptor species by
RT   selective immunoprecipitation and immunoblotting.";
RL   Biochem. J. 327:209-215(1997).
RN   [15]
RP   INTERACTION WITH 14-3-3 PROTEINS.
RX   PubMed=9581554; DOI=10.1042/bj3270765;
RA   Furlanetto R.W., Dey B.R., Lopaczynski W., Nissley S.P.;
RT   "14-3-3 proteins interact with the insulin-like growth factor receptor
RT   but not the insulin receptor.";
RL   Biochem. J. 327:765-771(1997).
RN   [16]
RP   FORMATION OF A HYBRID RECEPTOR WITH INSR, AND TISSUE SPECIFICITY.
RX   PubMed=9202395; DOI=10.1016/S0303-7207(97)04050-1;
RA   Federici M., Porzio O., Zucaro L., Fusco A., Borboni P., Lauro D.,
RA   Sesti G.;
RT   "Distribution of insulin/insulin-like growth factor-I hybrid receptors
RT   in human tissues.";
RL   Mol. Cell. Endocrinol. 129:121-126(1997).
RN   [17]
RP   INTERACTION WITH SOCS1 AND SOCS2.
RX   PubMed=9727029; DOI=10.1074/jbc.273.37.24095;
RA   Dey B.R., Spence S.L., Nissley P., Furlanetto R.W.;
RT   "Interaction of human suppressor of cytokine signaling (SOCS)-2 with
RT   the insulin-like growth factor-I receptor.";
RL   J. Biol. Chem. 273:24095-24101(1998).
RN   [18]
RP   INTERACTION WITH ARRB1 AND ARRB2.
RX   PubMed=9822622; DOI=10.1074/jbc.273.48.31640;
RA   Lin F.-T., Daaka Y., Lefkowitz R.J.;
RT   "beta-arrestins regulate mitogenic signaling and clathrin-mediated
RT   endocytosis of the insulin-like growth factor I receptor.";
RL   J. Biol. Chem. 273:31640-31643(1998).
RN   [19]
RP   FUNCTION IN CANCER.
RX   PubMed=10579905; DOI=10.1006/excr.1999.4667;
RA   Baserga R.;
RT   "The IGF-I receptor in cancer research.";
RL   Exp. Cell Res. 253:1-6(1999).
RN   [20]
RP   INTERACTION WITH GRB10, AND MUTAGENESIS OF TYR-980; TYR-1280; TYR-1281
RP   AND TYR-1346.
RX   PubMed=10454568; DOI=10.1128/MCB.19.9.6217;
RA   Wang J., Dai H., Yousaf N., Moussaif M., Deng Y., Boufelliga A.,
RA   Swamy O.R., Leone M.E., Riedel H.;
RT   "Grb10, a positive, stimulatory signaling adapter in platelet-derived
RT   growth factor BB-, insulin-like growth factor I-, and insulin-mediated
RT   mitogenesis.";
RL   Mol. Cell. Biol. 19:6217-6228(1999).
RN   [21]
RP   INTERACTION WITH SOCS3.
RX   PubMed=11071852; DOI=10.1006/bbrc.2000.3762;
RA   Dey B.R., Furlanetto R.W., Nissley P.;
RT   "Suppressor of cytokine signaling (SOCS)-3 protein interacts with the
RT   insulin-like growth factor-I receptor.";
RL   Biochem. Biophys. Res. Commun. 278:38-43(2000).
RN   [22]
RP   AUTOPHOSPHORYLATION.
RX   PubMed=11162456; DOI=10.1006/bbrc.2000.4046;
RA   Lopaczynski W., Terry C., Nissley P.;
RT   "Autophosphorylation of the insulin-like growth factor I receptor
RT   cytoplasmic domain.";
RL   Biochem. Biophys. Res. Commun. 279:955-960(2000).
RN   [23]
RP   FUNCTION IN ACTIVATION OF STAT3.
RX   PubMed=10747872; DOI=10.1074/jbc.M000089200;
RA   Zong C.S., Chan J., Levy D.E., Horvath C., Sadowski H.B., Wang L.H.;
RT   "Mechanism of STAT3 activation by insulin-like growth factor I
RT   receptor.";
RL   J. Biol. Chem. 275:15099-15105(2000).
RN   [24]
RP   TISSUE SPECIFICITY.
RX   PubMed=12019176;
RA   Hellawell G.O., Turner G.D., Davies D.R., Poulsom R., Brewster S.F.,
RA   Macaulay V.M.;
RT   "Expression of the type 1 insulin-like growth factor receptor is up-
RT   regulated in primary prostate cancer and commonly persists in
RT   metastatic disease.";
RL   Cancer Res. 62:2942-2950(2002).
RN   [25]
RP   FUNCTION, AND FORMATION OF A HYBRID RECEPTOR WITH INSR.
RX   PubMed=12138094; DOI=10.1074/jbc.M202766200;
RA   Pandini G., Frasca F., Mineo R., Sciacca L., Vigneri R., Belfiore A.;
RT   "Insulin/insulin-like growth factor I hybrid receptors have different
RT   biological characteristics depending on the insulin receptor isoform
RT   involved.";
RL   J. Biol. Chem. 277:39684-39695(2002).
RN   [26]
RP   INTERACTION WITH RACK1.
RX   PubMed=11884618; DOI=10.1128/MCB.22.7.2345-2365.2002;
RA   Hermanto U., Zong C.S., Li W., Wang L.H.;
RT   "RACK1, an insulin-like growth factor I (IGF-I) receptor-interacting
RT   protein, modulates IGF-I-dependent integrin signaling and promotes
RT   cell spreading and contact with extracellular matrix.";
RL   Mol. Cell. Biol. 22:2345-2365(2002).
RN   [27]
RP   FUNCTION, AND INTERACTION WITH MAP3K5.
RX   PubMed=12556535; DOI=10.1074/jbc.M211398200;
RA   Galvan V., Logvinova A., Sperandio S., Ichijo H., Bredesen D.E.;
RT   "Type 1 insulin-like growth factor receptor (IGF-IR) signaling
RT   inhibits apoptosis signal-regulating kinase 1 (ASK1).";
RL   J. Biol. Chem. 278:13325-13332(2003).
RN   [28]
RP   UBIQUITINATION BY MDM2, AND INTERACTION WITH MDM2.
RX   PubMed=12821780; DOI=10.1073/pnas.1431613100;
RA   Girnita L., Girnita A., Larsson O.;
RT   "Mdm2-dependent ubiquitination and degradation of the insulin-like
RT   growth factor 1 receptor.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:8247-8252(2003).
RN   [29]
RP   ENZYME REGULATION.
RX   PubMed=14729630; DOI=10.1158/0008-5472.CAN-03-2522;
RA   Girnita A., Girnita L., del Prete F., Bartolazzi A., Larsson O.,
RA   Axelson M.;
RT   "Cyclolignans as inhibitors of the insulin-like growth factor-1
RT   receptor and malignant cell growth.";
RL   Cancer Res. 64:236-242(2004).
RN   [30]
RP   INTERACTION WITH ARRB1 AND ARRB2.
RX   PubMed=15878855; DOI=10.1074/jbc.M501129200;
RA   Girnita L., Shenoy S.K., Sehat B., Vasilcanu R., Girnita A.,
RA   Lefkowitz R.J., Larsson O.;
RT   "{beta}-Arrestin is crucial for ubiquitination and down-regulation of
RT   the insulin-like growth factor-1 receptor by acting as adaptor for the
RT   MDM2 E3 ligase.";
RL   J. Biol. Chem. 280:24412-24419(2005).
RN   [31]
RP   INTERACTION WITH STAT3.
RX   PubMed=15998644; DOI=10.1074/jbc.M501316200;
RA   Yadav A., Kalita A., Dhillon S., Banerjee K.;
RT   "JAK/STAT3 pathway is involved in survival of neurons in response to
RT   insulin-like growth factor and negatively regulated by suppressor of
RT   cytokine signaling-3.";
RL   J. Biol. Chem. 280:31830-31840(2005).
RN   [32]
RP   FUNCTION, AND FORMATION OF A HYBRID RECEPTOR WITH INSR.
RX   PubMed=16831875; DOI=10.1074/jbc.M605189200;
RA   Slaaby R., Schaeffer L., Lautrup-Larsen I., Andersen A.S., Shaw A.C.,
RA   Mathiasen I.S., Brandt J.;
RT   "Hybrid receptors formed by insulin receptor (IR) and insulin-like
RT   growth factor I receptor (IGF-IR) have low insulin and high IGF-1
RT   affinity irrespective of the IR splice variant.";
RL   J. Biol. Chem. 281:25869-25874(2006).
RN   [33]
RP   SUBCELLULAR LOCATION, AND PROTEOLYTIC PROCESSING.
RX   PubMed=17524361; DOI=10.1016/j.bbrc.2007.05.062;
RA   McElroy B., Powell J.C., McCarthy J.V.;
RT   "The insulin-like growth factor 1 (IGF-1) receptor is a substrate for
RT   gamma-secretase-mediated intramembrane proteolysis.";
RL   Biochem. Biophys. Res. Commun. 358:1136-1141(2007).
RN   [34]
RP   REVIEW ON IGF1R IN CANCER.
RX   PubMed=17624760; DOI=10.1016/j.ejca.2007.05.021;
RA   Hartog H., Wesseling J., Boezen H.M., van der Graaf W.T.;
RT   "The insulin-like growth factor 1 receptor in cancer: old focus, new
RT   future.";
RL   Eur. J. Cancer 43:1895-1904(2007).
RN   [35]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [36]
RP   BINDING TO IGF1, AND IDENTIFICATION IN A COMPLEX WITH INTEGRIN AND
RP   IGF1.
RX   PubMed=19578119; DOI=10.1074/jbc.M109.013201;
RA   Saegusa J., Yamaji S., Ieguchi K., Wu C.Y., Lam K.S., Liu F.T.,
RA   Takada Y.K., Takada Y.;
RT   "The direct binding of insulin-like growth factor-1 (IGF-1) to
RT   integrin alphavbeta3 is involved in IGF-1 signaling.";
RL   J. Biol. Chem. 284:24106-24114(2009).
RN   [37]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [38]
RP   SUMOYLATION.
RX   PubMed=20596523; DOI=10.1371/journal.pone.0011332;
RA   Del Rincon S.V., Rogers J., Widschwendter M., Sun D., Sieburg H.B.,
RA   Spruck C.;
RT   "Development and validation of a method for profiling post-
RT   translational modification activities using protein microarrays.";
RL   PLoS ONE 5:E11332-E11332(2010).
RN   [39]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [40]
RP   UBIQUITINATION AT LYS-1168 AND LYS-1171.
RX   PubMed=21994939; DOI=10.1074/jbc.M111.288514;
RA   Mao Y., Shang Y., Pham V.C., Ernst J.A., Lill J.R., Scales S.J.,
RA   Zha J.;
RT   "Polyubiquitination of insulin-like growth factor I receptor (IGF-IR)
RT   activation loop promotes antibody-induced receptor internalization and
RT   down-regulation.";
RL   J. Biol. Chem. 286:41852-41861(2011).
RN   [41]
RP   BINDING TO IGF1, AND IDENTIFICATION IN A COMPLEX WITH INTEGRIN AND
RP   IGF1.
RX   PubMed=22351760; DOI=10.1074/jbc.M111.304170;
RA   Fujita M., Ieguchi K., Davari P., Yamaji S., Taniguchi Y.,
RA   Sekiguchi K., Takada Y.K., Takada Y.;
RT   "Cross-talk between integrin alpha6beta4 and insulin-like growth
RT   factor-1 receptor (IGF1R) through direct alpha6beta4 binding to IGF1
RT   and subsequent alpha6beta4-IGF1-IGF1R ternary complex formation in
RT   anchorage-independent conditions.";
RL   J. Biol. Chem. 287:12491-12500(2012).
RN   [42]
RP   X-RAY CRYSTALLOGRAPHY (2.60 ANGSTROMS) OF 31-492, DISULFIDE BONDS, AND
RP   GLYCOSYLATION AT ASN-51; ASN-135; ASN-244 AND ASN-314.
RX   PubMed=9690478; DOI=10.1038/28668;
RA   Garrett T.P., McKern N.M., Lou M., Frenkel M.J., Bentley J.D.,
RA   Lovrecz G.O., Elleman T.C., Cosgrove L.J., Ward C.W.;
RT   "Crystal structure of the first three domains of the type-1 insulin-
RT   like growth factor receptor.";
RL   Nature 394:395-399(1998).
RN   [43]
RP   X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) OF 988-1286 IN COMPLEX WITH
RP   AMP-PCP AND PEPTIDE SUBSTRATE, CATALYTIC ACTIVITY, ACTIVE SITE, ENZYME
RP   REGULATION, IDENTIFICATION BY MASS SPECTROMETRY, AND PHOSPHORYLATION
RP   AT TYR-1161; TYR-1165 AND TYR-1166.
RX   PubMed=11694888; DOI=10.1038/nsb721;
RA   Favelyukis S., Till J.H., Hubbard S.R., Miller W.T.;
RT   "Structure and autoregulation of the insulin-like growth factor 1
RT   receptor kinase.";
RL   Nat. Struct. Biol. 8:1058-1063(2001).
RN   [44]
RP   X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) OF 981-1286 IN COMPLEX WITH
RP   ANP, AUTOPHOSPHORYLATION, ACTIVE SITE, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RX   PubMed=11591350; DOI=10.1016/S0969-2126(01)00655-4;
RA   Pautsch A., Zoephel A., Ahorn H., Spevak W., Hauptmann R., Nar H.;
RT   "Crystal structure of bisphosphorylated IGF-1 receptor kinase: insight
RT   into domain movements upon kinase activation.";
RL   Structure 9:955-965(2001).
RN   [45]
RP   X-RAY CRYSTALLOGRAPHY (2.70 ANGSTROMS) OF 974-1294.
RX   PubMed=12138114; DOI=10.1074/jbc.M205580200;
RA   Munshi S., Kornienko M., Hall D.L., Reid J.C., Waxman L.,
RA   Stirdivant S.M., Darke P.L., Kuo L.C.;
RT   "Crystal structure of the Apo, unactivated insulin-like growth factor-
RT   1 receptor kinase. Implication for inhibitor specificity.";
RL   J. Biol. Chem. 277:38797-38802(2002).
RN   [46]
RP   X-RAY CRYSTALLOGRAPHY (1.50 ANGSTROMS) OF 974-1294.
RX   PubMed=14501110; DOI=10.1107/S0907444903015415;
RA   Munshi S., Hall D.L., Kornienko M., Darke P.L., Kuo L.C.;
RT   "Structure of apo, unactivated insulin-like growth factor-1 receptor
RT   kinase at 1.5 A resolution.";
RL   Acta Crystallogr. D 59:1725-1730(2003).
RN   [47]
RP   X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 982-1286 IN COMPLEX WITH
RP   BENZIMIDAZOLE PYRIDINONE INHIBITOR, CATALYTIC ACTIVITY, AND ENZYME
RP   REGULATION.
RX   PubMed=17317169; DOI=10.1016/j.bmcl.2007.01.102;
RA   Velaparthi U., Wittman M., Liu P., Stoffan K., Zimmermann K., Sang X.,
RA   Carboni J., Li A., Attar R., Gottardis M., Greer A., Chang C.Y.,
RA   Jacobsen B.L., Sack J.S., Sun Y., Langley D.R., Balasubramanian B.,
RA   Vyas D.;
RT   "Discovery and initial SAR of 3-(1H-benzo[d]imidazol-2-yl)pyridin-
RT   2(1H)-ones as inhibitors of insulin-like growth factor 1-receptor
RT   (IGF-1R).";
RL   Bioorg. Med. Chem. Lett. 17:2317-2321(2007).
RN   [48]
RP   X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) OF 981-1286, AND
RP   PHOSPHORYLATION AT TYR-1161; TYR-1165 AND TYR-1166.
RX   PubMed=18501599; DOI=10.1016/j.bmcl.2008.04.044;
RA   Mayer S.C., Banker A.L., Boschelli F., Di L., Johnson M., Kenny C.H.,
RA   Krishnamurthy G., Kutterer K., Moy F., Petusky S., Ravi M., Tkach D.,
RA   Tsou H.R., Xu W.;
RT   "Lead identification to generate isoquinolinedione inhibitors of
RT   insulin-like growth factor receptor (IGF-1R) for potential use in
RT   cancer treatment.";
RL   Bioorg. Med. Chem. Lett. 18:3641-3645(2008).
RN   [49]
RP   X-RAY CRYSTALLOGRAPHY (2.30 ANGSTROMS) OF 986-1286 IN COMPLEX WITH
RP   INHIBITOR PQIP, SUBUNIT, AUTOPHOSPHORYLATION, CATALYTIC ACTIVITY,
RP   ACTIVE SITE, AND ENZYME REGULATION.
RX   PubMed=18566589; DOI=10.1038/emboj.2008.116;
RA   Wu J., Li W., Craddock B.P., Foreman K.W., Mulvihill M.J., Ji Q.S.,
RA   Miller W.T., Hubbard S.R.;
RT   "Small-molecule inhibition and activation-loop trans-phosphorylation
RT   of the IGF1 receptor.";
RL   EMBO J. 27:1985-1994(2008).
RN   [50]
RP   X-RAY CRYSTALLOGRAPHY (2.90 ANGSTROMS) OF 981-1286 IN COMPLEX WITH
RP   3-CYANOQUINOLINE INHIBITOR, CATALYTIC ACTIVITY, ENZYME REGULATION, AND
RP   PHOSPHORYLATION AT TYR-1161; TYR-1165 AND TYR-1166.
RX   PubMed=19041240; DOI=10.1016/j.bmcl.2008.11.037;
RA   Miller L.M., Mayer S.C., Berger D.M., Boschelli D.H., Boschelli F.,
RA   Di L., Du X., Dutia M., Floyd M.B., Johnson M., Kenny C.H.,
RA   Krishnamurthy G., Moy F., Petusky S., Tkach D., Torres N., Wu B.,
RA   Xu W.;
RT   "Lead identification to generate 3-cyanoquinoline inhibitors of
RT   insulin-like growth factor receptor (IGF-1R) for potential use in
RT   cancer treatment.";
RL   Bioorg. Med. Chem. Lett. 19:62-66(2009).
RN   [51]
RP   X-RAY CRYSTALLOGRAPHY (2.08 ANGSTROMS) OF 982-1286 IN COMPLEX WITH
RP   BMS-754807, CATALYTIC ACTIVITY, AND ENZYME REGULATION.
RX   PubMed=19778024; DOI=10.1021/jm900786r;
RA   Wittman M.D., Carboni J.M., Yang Z., Lee F.Y., Antman M., Attar R.,
RA   Balimane P., Chang C., Chen C., Discenza L., Frennesson D.,
RA   Gottardis M.M., Greer A., Hurlburt W., Johnson W., Langley D.R.,
RA   Li A., Li J., Liu P., Mastalerz H., Mathur A., Menard K., Patel K.,
RA   Sack J., Sang X., Saulnier M., Smith D., Stefanski K., Trainor G.,
RA   Velaparthi U., Zhang G., Zimmermann K., Vyas D.M.;
RT   "Discovery of a 2,4-disubstituted pyrrolo[1,2-f][1,2,4]triazine
RT   inhibitor (BMS-754807) of insulin-like growth factor receptor (IGF-1R)
RT   kinase in clinical development.";
RL   J. Med. Chem. 52:7360-7363(2009).
RN   [52]
RP   X-RAY CRYSTALLOGRAPHY (1.79 ANGSTROMS) OF 983-1286 IN COMPLEX WITH
RP   MSC1609119A-1, CATALYTIC ACTIVITY, AND ENZYME REGULATION.
RX   DOI=10.1021/ml100044h;
RA   Heinrich T., Graedler U., Boettcher H., Blaukat A., Shutes A.;
RT   "Allosteric IGF-1R Inhibitors.";
RL   ACS Med. Chem. Lett. 1:199-203(2010).
RN   [53]
RP   X-RAY CRYSTALLOGRAPHY (2.11 ANGSTROMS) OF 982-1286 IN COMPLEXES WITH
RP   INHIBITORS, CATALYTIC ACTIVITY, AND ENZYME REGULATION.
RX   PubMed=20675137; DOI=10.1016/j.bmcl.2010.07.045;
RA   Sampognaro A.J., Wittman M.D., Carboni J.M., Chang C., Greer A.F.,
RA   Hurlburt W.W., Sack J.S., Vyas D.M.;
RT   "Proline isosteres in a series of 2,4-disubstituted pyrrolo[1,2-
RT   f][1,2,4]triazine inhibitors of IGF-1R kinase and IR kinase.";
RL   Bioorg. Med. Chem. Lett. 20:5027-5030(2010).
RN   [54]
RP   X-RAY CRYSTALLOGRAPHY (3.00 ANGSTROMS) OF 951-1286 IN COMPLEX WITH
RP   BIS-AZAINDOLE INHIBITOR, AUTOPHOSPHORYLATION, AND ENZYME REGULATION.
RX   PubMed=20545947; DOI=10.1111/j.1747-0285.2010.00991.x;
RA   Nemecek C., Metz W.A., Wentzler S., Ding F.X., Venot C., Souaille C.,
RA   Dagallier A., Maignan S., Guilloteau J.P., Bernard F., Henry A.,
RA   Grapinet S., Lesuisse D.;
RT   "Design of potent IGF1-R inhibitors related to bis-azaindoles.";
RL   Chem. Biol. Drug Des. 76:100-106(2010).
RN   [55]
RP   X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) OF 982-1286 IN COMPLEX WITH
RP   HYDANTOIN DERIVATIVE, CATALYTIC ACTIVITY, AND ENZYME REGULATION.
RX   PubMed=21441024; DOI=10.1016/j.bmcl.2011.03.003;
RA   Lesuisse D., Mauger J., Nemecek C., Maignan S., Boiziau J., Harlow G.,
RA   Hittinger A., Ruf S., Strobel H., Nair A., Ritter K., Malleron J.L.,
RA   Dagallier A., El-Ahmad Y., Guilloteau J.P., Guizani H., Bouchard H.,
RA   Venot C.;
RT   "Discovery of the first non-ATP competitive IGF-1R kinase inhibitors:
RT   advantages in comparison with competitive inhibitors.";
RL   Bioorg. Med. Chem. Lett. 21:2224-2228(2011).
RN   [56]
RP   X-RAY CRYSTALLOGRAPHY (2.90 ANGSTROMS) OF 988-1286 IN COMPLEX WITH
RP   2,4-BIS-ARYLAMINO-1,3-PYRIMIDINE INHIBITOR, CATALYTIC ACTIVITY, AND
RP   ENZYME REGULATION.
RX   PubMed=21414779; DOI=10.1016/j.bmcl.2011.02.075;
RA   Buchanan J.L., Newcomb J.R., Carney D.P., Chaffee S.C., Chai L.,
RA   Cupples R., Epstein L.F., Gallant P., Gu Y., Harmange J.C., Hodge K.,
RA   Houk B.E., Huang X., Jona J., Joseph S., Jun H.T., Kumar R., Li C.,
RA   Lu J., Menges T., Morrison M.J., Novak P.M., van der Plas S.,
RA   Radinsky R., Rose P.E., Sawant S., Sun J.R., Surapaneni S.,
RA   Turci S.M., Xu K., Yanez E., Zhao H., Zhu X.;
RT   "Discovery of 2,4-bis-arylamino-1,3-pyrimidines as insulin-like growth
RT   factor-1 receptor (IGF-1R) inhibitors.";
RL   Bioorg. Med. Chem. Lett. 21:2394-2399(2011).
RN   [57]
RP   VARIANTS IGF1RES GLN-138 AND ASN-145, AND CHARACTERIZATION OF VARIANTS
RP   IGF1RES GLN-138 AND ASN-145.
RX   PubMed=14657428; DOI=10.1056/NEJMoa010107;
RG   The intrauterine growth retardation (IUGR) study group;
RA   Abuzzahab M.J., Schneider A., Goddard A., Grigorescu F., Lautier C.,
RA   Keller E., Kiess W., Klammt J., Kratzsch J., Osgood D., Pfaeffle R.,
RA   Raile K., Seidel B., Smith R.J., Chernausek S.D.;
RT   "IGF-I receptor mutations resulting in intrauterine and postnatal
RT   growth retardation.";
RL   N. Engl. J. Med. 349:2211-2222(2003).
RN   [58]
RP   VARIANT IGF1RES GLN-739, AND CHARACTERIZATION OF VARIANT IGF1RES
RP   GLN-739.
RX   PubMed=15928254; DOI=10.1210/jc.2004-1947;
RA   Kawashima Y., Kanzaki S., Yang F., Kinoshita T., Hanaki K.,
RA   Nagaishi J., Ohtsuka Y., Hisatome I., Ninomoya H., Nanba E.,
RA   Fukushima T., Takahashi S.;
RT   "Mutation at cleavage site of insulin-like growth factor receptor in a
RT   short-stature child born with intrauterine growth retardation.";
RL   J. Clin. Endocrinol. Metab. 90:4679-4687(2005).
RN   [59]
RP   VARIANTS [LARGE SCALE ANALYSIS] LEU-105; HIS-437; HIS-595; SER-857;
RP   THR-1338 AND VAL-1347.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [60]
RP   VARIANTS IGF1RES TYR-359; CYS-865; SER-1256 AND CYS-1337, AND
RP   CHARACTERIZATION OF VARIANTS IGF1RES TYR-359; CYS-865; SER-1256 AND
RP   CYS-1337.
RX   PubMed=25040157; DOI=10.1111/cen.12555;
RA   Juanes M., Guercio G., Marino R., Berensztein E., Warman D.M.,
RA   Ciaccio M., Gil S., Bailez M., Rivarola M.A., Belgorosky A.;
RT   "Three novel IGF1R mutations in microcephalic patients with prenatal
RT   and postnatal growth impairment.";
RL   Clin. Endocrinol. (Oxf.) 82:704-711(2015).
CC   -!- FUNCTION: Receptor tyrosine kinase which mediates actions of
CC       insulin-like growth factor 1 (IGF1). Binds IGF1 with high affinity
CC       and IGF2 and insulin (INS) with a lower affinity. The activated
CC       IGF1R is involved in cell growth and survival control. IGF1R is
CC       crucial for tumor transformation and survival of malignant cell.
CC       Ligand binding activates the receptor kinase, leading to receptor
CC       autophosphorylation, and tyrosines phosphorylation of multiple
CC       substrates, that function as signaling adapter proteins including,
CC       the insulin-receptor substrates (IRS1/2), Shc and 14-3-3 proteins.
CC       Phosphorylation of IRSs proteins lead to the activation of two
CC       main signaling pathways: the PI3K-AKT/PKB pathway and the Ras-MAPK
CC       pathway. The result of activating the MAPK pathway is increased
CC       cellular proliferation, whereas activating the PI3K pathway
CC       inhibits apoptosis and stimulates protein synthesis.
CC       Phosphorylated IRS1 can activate the 85 kDa regulatory subunit of
CC       PI3K (PIK3R1), leading to activation of several downstream
CC       substrates, including protein AKT/PKB. AKT phosphorylation, in
CC       turn, enhances protein synthesis through mTOR activation and
CC       triggers the antiapoptotic effects of IGFIR through
CC       phosphorylation and inactivation of BAD. In parallel to PI3K-
CC       driven signaling, recruitment of Grb2/SOS by phosphorylated IRS1
CC       or Shc leads to recruitment of Ras and activation of the ras-MAPK
CC       pathway. In addition to these two main signaling pathways IGF1R
CC       signals also through the Janus kinase/signal transducer and
CC       activator of transcription pathway (JAK/STAT). Phosphorylation of
CC       JAK proteins can lead to phosphorylation/activation of signal
CC       transducers and activators of transcription (STAT) proteins. In
CC       particular activation of STAT3, may be essential for the
CC       transforming activity of IGF1R. The JAK/STAT pathway activates
CC       gene transcription and may be responsible for the transforming
CC       activity. JNK kinases can also be activated by the IGF1R. IGF1
CC       exerts inhibiting activities on JNK activation via phosphorylation
CC       and inhibition of MAP3K5/ASK1, which is able to directly associate
CC       with the IGF1R.
CC   -!- FUNCTION: When present in a hybrid receptor with INSR, binds IGF1.
CC       PubMed:12138094 shows that hybrid receptors composed of IGF1R and
CC       INSR isoform Long are activated with a high affinity by IGF1, with
CC       low affinity by IGF2 and not significantly activated by insulin,
CC       and that hybrid receptors composed of IGF1R and INSR isoform Short
CC       are activated by IGF1, IGF2 and insulin. In contrast,
CC       PubMed:16831875 shows that hybrid receptors composed of IGF1R and
CC       INSR isoform Long and hybrid receptors composed of IGF1R and INSR
CC       isoform Short have similar binding characteristics, both bind IGF1
CC       and have a low affinity for insulin.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028, ECO:0000269|PubMed:11694888,
CC       ECO:0000269|PubMed:17317169, ECO:0000269|PubMed:18566589,
CC       ECO:0000269|PubMed:19041240, ECO:0000269|PubMed:19778024,
CC       ECO:0000269|PubMed:20675137, ECO:0000269|PubMed:21414779,
CC       ECO:0000269|PubMed:21441024, ECO:0000269|PubMed:7679099,
CC       ECO:0000269|Ref.52}.
CC   -!- ENZYME REGULATION: Activated by autophosphorylation at Tyr-1165,
CC       Tyr-1161 and Tyr-1166 on the kinase activation loop;
CC       phosphorylation at all three tyrosine residues is required for
CC       optimal kinase activity. Inhibited by MSC1609119A-1, BMS-754807,
CC       PQIP, benzimidazole pyridinone, isoquinolinedione, bis-azaindole,
CC       3-cyanoquinoline, 2,4-bis-arylamino-1,3-pyrimidine,
CC       pyrrolopyrimidine, pyrrole-5-carboxaldehyde, picropodophyllin
CC       (PPP), tyrphostin derivatives. While most inhibitors bind to the
CC       ATP binding pocket, MSC1609119A-1 functions as allosteric
CC       inhibitor and binds close to the DFG motif and the activation
CC       loop. {ECO:0000269|PubMed:11694888, ECO:0000269|PubMed:14729630,
CC       ECO:0000269|PubMed:17317169, ECO:0000269|PubMed:18566589,
CC       ECO:0000269|PubMed:19041240, ECO:0000269|PubMed:19778024,
CC       ECO:0000269|PubMed:20545947, ECO:0000269|PubMed:20675137,
CC       ECO:0000269|PubMed:21414779, ECO:0000269|PubMed:21441024,
CC       ECO:0000269|Ref.52}.
CC   -!- SUBUNIT: Tetramer of 2 alpha and 2 beta chains linked by disulfide
CC       bonds. The alpha chains contribute to the formation of the ligand-
CC       binding domain, while the beta chain carries the kinase domain.
CC       Interacts with PIK3R1 and with the PTB/PID domains of IRS1 and
CC       SHC1 in vitro when autophosphorylated on tyrosine residues. Forms
CC       a hybrid receptor with INSR, the hybrid is a tetramer consisting
CC       of 1 alpha chain and 1 beta chain of INSR and 1 alpha chain and 1
CC       beta chain of IGF1R. Interacts with ARRB1 and ARRB2. Interacts
CC       with GRB10. Interacts with RACK1. Interacts with SOCS1, SOCS2 and
CC       SOCS3. Interacts with 14-3-3 proteins. Interacts with NMD2.
CC       Interacts with MAP3K5. Interacts with STAT3. Found in a ternary
CC       complex with IGF1 and ITGAV:ITGB3 or ITGA6:ITGB4 (PubMed:19578119,
CC       PubMed:22351760). {ECO:0000269|PubMed:10454568,
CC       ECO:0000269|PubMed:11071852, ECO:0000269|PubMed:11591350,
CC       ECO:0000269|PubMed:11694888, ECO:0000269|PubMed:11884618,
CC       ECO:0000269|PubMed:12556535, ECO:0000269|PubMed:12821780,
CC       ECO:0000269|PubMed:15878855, ECO:0000269|PubMed:15998644,
CC       ECO:0000269|PubMed:17317169, ECO:0000269|PubMed:1846292,
CC       ECO:0000269|PubMed:18566589, ECO:0000269|PubMed:19041240,
CC       ECO:0000269|PubMed:19578119, ECO:0000269|PubMed:19778024,
CC       ECO:0000269|PubMed:20545947, ECO:0000269|PubMed:21414779,
CC       ECO:0000269|PubMed:21441024, ECO:0000269|PubMed:22351760,
CC       ECO:0000269|PubMed:7541045, ECO:0000269|PubMed:9581554,
CC       ECO:0000269|PubMed:9727029, ECO:0000269|PubMed:9822622,
CC       ECO:0000269|Ref.52}.
CC   -!- INTERACTION:
CC       Self; NbExp=3; IntAct=EBI-475981, EBI-475981;
CC       Q9NZN5:ARHGEF12; NbExp=7; IntAct=EBI-475981, EBI-821440;
CC       P49913:CAMP; NbExp=3; IntAct=EBI-475981, EBI-6378485;
CC       Q64010:Crk (xeno); NbExp=3; IntAct=EBI-475981, EBI-2906540;
CC       P41240:CSK; NbExp=5; IntAct=EBI-475981, EBI-1380630;
CC       P35222:CTNNB1; NbExp=3; IntAct=EBI-475981, EBI-491549;
CC       P05019:IGF1; NbExp=5; IntAct=EBI-475981, EBI-7902275;
CC       P01317:INS (xeno); NbExp=4; IntAct=EBI-475981, EBI-3989070;
CC       Q9Y2W7:KCNIP3; NbExp=5; IntAct=EBI-475981, EBI-751501;
CC       Q9UJU2:LEF1; NbExp=5; IntAct=EBI-475981, EBI-926131;
CC       Q00987:MDM2; NbExp=2; IntAct=EBI-475981, EBI-389668;
CC       P27986:PIK3R1; NbExp=4; IntAct=EBI-475981, EBI-79464;
CC       P18031:PTPN1; NbExp=3; IntAct=EBI-475981, EBI-968788;
CC       Q06124:PTPN11; NbExp=3; IntAct=EBI-475981, EBI-297779;
CC       P29353-2:SHC1; NbExp=2; IntAct=EBI-475981, EBI-1000553;
CC       Q01995:TAGLN; NbExp=2; IntAct=EBI-475981, EBI-1054248;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:17524361};
CC       Single-pass type I membrane protein {ECO:0000269|PubMed:17524361}.
CC   -!- TISSUE SPECIFICITY: Found as a hybrid receptor with INSR in
CC       muscle, heart, kidney, adipose tissue, skeletal muscle, hepatoma,
CC       fibroblasts, spleen and placenta (at protein level). Expressed in
CC       a variety of tissues. Overexpressed in tumors, including
CC       melanomas, cancers of the colon, pancreas prostate and kidney.
CC       {ECO:0000269|PubMed:12019176, ECO:0000269|PubMed:8247543,
CC       ECO:0000269|PubMed:9202395, ECO:0000269|PubMed:9355755}.
CC   -!- PTM: Autophosphorylated on tyrosine residues in response to ligand
CC       binding. Autophosphorylation occurs in trans, i.e. one subunit of
CC       the dimeric receptor phosphorylates tyrosine residues on the other
CC       subunit. Autophosphorylation occurs in a sequential manner; Tyr-
CC       1165 is predominantly phosphorylated first, followed by
CC       phosphorylation of Tyr-1161 and Tyr-1166. While every single
CC       phosphorylation increases kinase activity, all three tyrosine
CC       residues in the kinase activation loop (Tyr-1165, Tyr-1161 and
CC       Tyr-1166) have to be phosphorylated for optimal activity. Can be
CC       autophosphorylated at additional tyrosine residues (in vitro).
CC       Autophosphorylated is followed by phosphorylation of juxtamembrane
CC       tyrosines and C-terminal serines. Phosphorylation of Tyr-980 is
CC       required for IRS1- and SHC1-binding. Phosphorylation of Ser-1278
CC       by GSK-3beta restrains kinase activity and promotes cell surface
CC       expression, it requires a priming phosphorylation at Ser-1282.
CC       Dephosphorylated by PTPN1 (By similarity). {ECO:0000250}.
CC   -!- PTM: Polyubiquitinated at Lys-1168 and Lys-1171 through both 'Lys-
CC       48' and 'Lys-29' linkages, promoting receptor endocytosis and
CC       subsequent degradation by the proteasome. Ubiquitination is
CC       facilitated by pre-existing phosphorylation.
CC       {ECO:0000269|PubMed:11694888, ECO:0000269|PubMed:12821780,
CC       ECO:0000269|PubMed:18501599, ECO:0000269|PubMed:19041240,
CC       ECO:0000269|PubMed:21994939, ECO:0000269|PubMed:7541045}.
CC   -!- PTM: Sumoylated with SUMO1. {ECO:0000269|PubMed:20596523}.
CC   -!- PTM: Controlled by regulated intramembrane proteolysis (RIP).
CC       Undergoes metalloprotease-dependent constitutive ectodomain
CC       shedding to produce a membrane-anchored 52 kDa C-Terminal fragment
CC       which is further processed by presenilin gamma-secretase to yield
CC       an intracellular 50 kDa fragment. {ECO:0000269|PubMed:17524361}.
CC   -!- DISEASE: Insulin-like growth factor 1 resistance (IGF1RES)
CC       [MIM:270450]: A disorder characterized by intrauterine growth
CC       retardation, poor postnatal growth and increased plasma IGF1
CC       levels. {ECO:0000269|PubMed:14657428, ECO:0000269|PubMed:15928254,
CC       ECO:0000269|PubMed:25040157}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. Insulin receptor subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAG11657.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/IGF1RID40928ch15q26.html";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/igf1r/";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=IGF-1 receptor entry;
CC       URL="https://en.wikipedia.org/wiki/IGF-1_receptor";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X04434; CAA28030.1; -; mRNA.
DR   EMBL; AB425196; BAG11657.1; ALT_INIT; mRNA.
DR   EMBL; AY332722; AAP81165.1; -; Genomic_DNA.
DR   EMBL; AC055807; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC069029; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC118658; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC118660; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC113610; AAI13611.1; -; mRNA.
DR   EMBL; BC113612; AAI13613.1; -; mRNA.
DR   EMBL; M69229; AAB59399.1; -; Genomic_DNA.
DR   CCDS; CCDS10378.1; -.
DR   PIR; A25690; IGHUR1.
DR   RefSeq; NP_000866.1; NM_000875.4.
DR   RefSeq; NP_001278787.1; NM_001291858.1.
DR   UniGene; Hs.643120; -.
DR   UniGene; Hs.714012; -.
DR   PDB; 1IGR; X-ray; 2.60 A; A=31-492.
DR   PDB; 1JQH; X-ray; 2.10 A; A/B/C=979-1286.
DR   PDB; 1K3A; X-ray; 2.10 A; A=988-1286.
DR   PDB; 1M7N; X-ray; 2.70 A; A/B=974-1294.
DR   PDB; 1P4O; X-ray; 1.50 A; A/B=974-1294.
DR   PDB; 2OJ9; X-ray; 2.00 A; A=982-1286.
DR   PDB; 2ZM3; X-ray; 2.50 A; A/B/C/D=981-1286.
DR   PDB; 3D94; X-ray; 2.30 A; A=986-1286.
DR   PDB; 3F5P; X-ray; 2.90 A; A/B/C/D/E/F/G/H/I/J/K/L/M/R/S/T=981-1286.
DR   PDB; 3I81; X-ray; 2.08 A; A=982-1286.
DR   PDB; 3LVP; X-ray; 3.00 A; A/B/C/D=951-1286.
DR   PDB; 3LW0; X-ray; 1.79 A; A/B/C/D=983-1286.
DR   PDB; 3NW5; X-ray; 2.14 A; A=982-1286.
DR   PDB; 3NW6; X-ray; 2.20 A; A=982-1286.
DR   PDB; 3NW7; X-ray; 2.11 A; A=982-1286.
DR   PDB; 3O23; X-ray; 2.10 A; A=982-1286.
DR   PDB; 3QQU; X-ray; 2.90 A; A/B/C/D=988-1286.
DR   PDB; 4D2R; X-ray; 2.10 A; A=985-1286.
DR   PDB; 4XSS; X-ray; 3.00 A; F=721-736.
DR   PDB; 5FXQ; X-ray; 2.30 A; A=980-1286.
DR   PDB; 5FXR; X-ray; 2.40 A; A=980-1286.
DR   PDB; 5FXS; X-ray; 1.90 A; A=980-1286.
DR   PDB; 5HZN; X-ray; 2.20 A; A/B/C/D/E/F/G/H=983-1286.
DR   PDBsum; 1IGR; -.
DR   PDBsum; 1JQH; -.
DR   PDBsum; 1K3A; -.
DR   PDBsum; 1M7N; -.
DR   PDBsum; 1P4O; -.
DR   PDBsum; 2OJ9; -.
DR   PDBsum; 2ZM3; -.
DR   PDBsum; 3D94; -.
DR   PDBsum; 3F5P; -.
DR   PDBsum; 3I81; -.
DR   PDBsum; 3LVP; -.
DR   PDBsum; 3LW0; -.
DR   PDBsum; 3NW5; -.
DR   PDBsum; 3NW6; -.
DR   PDBsum; 3NW7; -.
DR   PDBsum; 3O23; -.
DR   PDBsum; 3QQU; -.
DR   PDBsum; 4D2R; -.
DR   PDBsum; 4XSS; -.
DR   PDBsum; 5FXQ; -.
DR   PDBsum; 5FXR; -.
DR   PDBsum; 5FXS; -.
DR   PDBsum; 5HZN; -.
DR   ProteinModelPortal; P08069; -.
DR   SMR; P08069; -.
DR   BioGrid; 109701; 73.
DR   DIP; DIP-476N; -.
DR   IntAct; P08069; 54.
DR   MINT; MINT-85902; -.
DR   STRING; 9606.ENSP00000268035; -.
DR   BindingDB; P08069; -.
DR   ChEMBL; CHEMBL1957; -.
DR   DrugBank; DB07474; 3-[5-(1H-IMIDAZOL-1-YL)-7-METHYL-1H-BENZIMIDAZOL-2-YL]-4-[(PYRIDIN-2-YLMETHYL)AMINO]PYRIDIN-2(1H)-ONE.
DR   DrugBank; DB05023; ATL1101.
DR   DrugBank; DB05759; IMC-A12.
DR   DrugBank; DB05900; INSM-18.
DR   DrugBank; DB00047; Insulin Glargine.
DR   DrugBank; DB00030; Insulin Human.
DR   DrugBank; DB00046; Insulin Lispro.
DR   DrugBank; DB00071; Insulin Pork.
DR   DrugBank; DB01277; Mecasermin.
DR   DrugBank; DB04395; Phosphoaminophosphonic Acid-Adenylate Ester.
DR   DrugBank; DB05897; rhIGFBP-3.
DR   DrugBank; DB05184; XL228.
DR   GuidetoPHARMACOLOGY; 1801; -.
DR   iPTMnet; P08069; -.
DR   PhosphoSitePlus; P08069; -.
DR   BioMuta; IGF1R; -.
DR   DMDM; 124240; -.
DR   EPD; P08069; -.
DR   MaxQB; P08069; -.
DR   PaxDb; P08069; -.
DR   PeptideAtlas; P08069; -.
DR   PRIDE; P08069; -.
DR   DNASU; 3480; -.
DR   Ensembl; ENST00000268035; ENSP00000268035; ENSG00000140443.
DR   GeneID; 3480; -.
DR   KEGG; hsa:3480; -.
DR   UCSC; uc002bul.4; human.
DR   CTD; 3480; -.
DR   DisGeNET; 3480; -.
DR   GeneCards; IGF1R; -.
DR   HGNC; HGNC:5465; IGF1R.
DR   HPA; CAB010268; -.
DR   HPA; HPA045563; -.
DR   MalaCards; IGF1R; -.
DR   MIM; 147370; gene.
DR   MIM; 270450; phenotype.
DR   neXtProt; NX_P08069; -.
DR   OpenTargets; ENSG00000140443; -.
DR   Orphanet; 73273; Growth delay due to insulin-like growth factor I resistance.
DR   PharmGKB; PA29698; -.
DR   eggNOG; KOG4258; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   GeneTree; ENSGT00760000118818; -.
DR   HOGENOM; HOG000038045; -.
DR   HOVERGEN; HBG006134; -.
DR   InParanoid; P08069; -.
DR   KO; K05087; -.
DR   OMA; GYLYRHN; -.
DR   OrthoDB; EOG091G00GE; -.
DR   PhylomeDB; P08069; -.
DR   TreeFam; TF351636; -.
DR   BRENDA; 2.7.10.1; 2681.
DR   Reactome; R-HSA-2404192; Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R).
DR   Reactome; R-HSA-2428928; IRS-related events triggered by IGF1R.
DR   Reactome; R-HSA-2428933; SHC-related events triggered by IGF1R.
DR   SignaLink; P08069; -.
DR   SIGNOR; P08069; -.
DR   ChiTaRS; IGF1R; human.
DR   EvolutionaryTrace; P08069; -.
DR   GeneWiki; Insulin-like_growth_factor_1_receptor; -.
DR   GenomeRNAi; 3480; -.
DR   PRO; PR:P08069; -.
DR   Proteomes; UP000005640; Chromosome 15.
DR   Bgee; ENSG00000140443; -.
DR   CleanEx; HS_IGF1R; -.
DR   ExpressionAtlas; P08069; baseline and differential.
DR   Genevisible; P08069; HS.
DR   GO; GO:0035867; C:alphav-beta3 integrin-IGF-1-IGF1R complex; IDA:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; IC:UniProtKB.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:BHF-UCL.
DR   GO; GO:0016020; C:membrane; IDA:BHF-UCL.
DR   GO; GO:0005886; C:plasma membrane; ISS:AgBase.
DR   GO; GO:0043235; C:receptor complex; IDA:MGI.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0043559; F:insulin binding; IPI:BHF-UCL.
DR   GO; GO:0005158; F:insulin receptor binding; IDA:BHF-UCL.
DR   GO; GO:0043560; F:insulin receptor substrate binding; IPI:UniProtKB.
DR   GO; GO:0005520; F:insulin-like growth factor binding; IDA:UniProtKB.
DR   GO; GO:0031994; F:insulin-like growth factor I binding; IDA:UniProtKB.
DR   GO; GO:0005010; F:insulin-like growth factor-activated receptor activity; IDA:UniProtKB.
DR   GO; GO:0043548; F:phosphatidylinositol 3-kinase binding; IPI:UniProtKB.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0006955; P:immune response; IMP:BHF-UCL.
DR   GO; GO:0051389; P:inactivation of MAPKK activity; IDA:UniProtKB.
DR   GO; GO:0008286; P:insulin receptor signaling pathway; TAS:ProtInc.
DR   GO; GO:0048009; P:insulin-like growth factor receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IDA:UniProtKB.
DR   GO; GO:0038083; P:peptidyl-tyrosine autophosphorylation; IMP:MGI.
DR   GO; GO:0014065; P:phosphatidylinositol 3-kinase signaling; IC:BHF-UCL.
DR   GO; GO:0048015; P:phosphatidylinositol-mediated signaling; IDA:BHF-UCL.
DR   GO; GO:0030335; P:positive regulation of cell migration; IMP:BHF-UCL.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; TAS:ProtInc.
DR   GO; GO:0045740; P:positive regulation of DNA replication; IMP:BHF-UCL.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0051262; P:protein tetramerization; IDA:UniProtKB.
DR   GO; GO:0046328; P:regulation of JNK cascade; IDA:UniProtKB.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   CDD; cd00063; FN3; 3.
DR   Gene3D; 2.60.40.10; -; 3.
DR   Gene3D; 3.80.20.20; -; 3.
DR   InterPro; IPR003961; FN3_dom.
DR   InterPro; IPR006211; Furin-like_Cys-rich_dom.
DR   InterPro; IPR006212; Furin_repeat.
DR   InterPro; IPR009030; Growth_fac_rcpt_.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR032675; L_dom-like.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR000494; Rcpt_L-dom.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR016246; Tyr_kinase_insulin-like_rcpt.
DR   InterPro; IPR002011; Tyr_kinase_rcpt_2_CS.
DR   Pfam; PF00757; Furin-like; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF01030; Recep_L_domain; 2.
DR   PIRSF; PIRSF000620; Insulin_receptor; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00060; FN3; 3.
DR   SMART; SM00261; FU; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF49265; SSF49265; 4.
DR   SUPFAM; SSF52058; SSF52058; 2.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   SUPFAM; SSF57184; SSF57184; 1.
DR   PROSITE; PS50853; FN3; 4.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS00239; RECEPTOR_TYR_KIN_II; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ATP-binding; Cell membrane;
KW   Cleavage on pair of basic residues; Complete proteome;
KW   Direct protein sequencing; Disease mutation; Disulfide bond;
KW   Glycoprotein; Isopeptide bond; Kinase; Membrane; Nucleotide-binding;
KW   Phosphoprotein; Polymorphism; Receptor; Reference proteome; Repeat;
KW   Signal; Transferase; Transmembrane; Transmembrane helix;
KW   Tyrosine-protein kinase; Ubl conjugation.
FT   SIGNAL        1     30       {ECO:0000269|PubMed:2877871,
FT                                ECO:0000269|PubMed:8257688}.
FT   CHAIN        31    736       Insulin-like growth factor 1 receptor
FT                                alpha chain.
FT                                /FTId=PRO_0000016681.
FT   CHAIN       741   1367       Insulin-like growth factor 1 receptor
FT                                beta chain.
FT                                /FTId=PRO_0000016682.
FT   TOPO_DOM    741    935       Extracellular. {ECO:0000255}.
FT   TRANSMEM    936    959       Helical. {ECO:0000255}.
FT   TOPO_DOM    960   1367       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN      491    609       Fibronectin type-III 1.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      610    708       Fibronectin type-III 2.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      735    828       Fibronectin type-III 3.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      834    927       Fibronectin type-III 4.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      999   1274       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND    1005   1013       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOTIF       977    980       IRS1- and SHC1-binding.
FT   ACT_SITE   1135   1135       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028}.
FT   BINDING    1033   1033       ATP.
FT   MOD_RES     980    980       Phosphotyrosine.
FT                                {ECO:0000305|PubMed:7541045}.
FT   MOD_RES    1161   1161       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:11694888,
FT                                ECO:0000269|PubMed:18501599,
FT                                ECO:0000269|PubMed:19041240}.
FT   MOD_RES    1165   1165       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:11694888,
FT                                ECO:0000269|PubMed:18501599,
FT                                ECO:0000269|PubMed:19041240}.
FT   MOD_RES    1166   1166       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:11694888,
FT                                ECO:0000269|PubMed:18501599,
FT                                ECO:0000269|PubMed:19041240}.
FT   MOD_RES    1278   1278       Phosphoserine; by GSK3-beta.
FT                                {ECO:0000250}.
FT   MOD_RES    1282   1282       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q60751}.
FT   CARBOHYD     51     51       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:9690478}.
FT   CARBOHYD    102    102       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    135    135       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:9690478}.
FT   CARBOHYD    244    244       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:9690478}.
FT   CARBOHYD    314    314       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:9690478}.
FT   CARBOHYD    417    417       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    438    438       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    534    534       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    607    607       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    622    622       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    640    640       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    747    747       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    756    756       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    764    764       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    900    900       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    913    913       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   DISULFID     33     52       {ECO:0000269|PubMed:9690478}.
FT   DISULFID    150    178       {ECO:0000269|PubMed:9690478}.
FT   DISULFID    182    205       {ECO:0000269|PubMed:9690478}.
FT   DISULFID    192    211       {ECO:0000269|PubMed:9690478}.
FT   DISULFID    215    224       {ECO:0000269|PubMed:9690478}.
FT   DISULFID    219    230       {ECO:0000269|PubMed:9690478}.
FT   DISULFID    231    239       {ECO:0000269|PubMed:9690478}.
FT   DISULFID    235    248       {ECO:0000269|PubMed:9690478}.
FT   DISULFID    251    260       {ECO:0000269|PubMed:9690478}.
FT   DISULFID    264    276       {ECO:0000269|PubMed:9690478}.
FT   DISULFID    282    303       {ECO:0000269|PubMed:9690478}.
FT   DISULFID    307    321       {ECO:0000269|PubMed:9690478}.
FT   DISULFID    324    328       {ECO:0000269|PubMed:9690478}.
FT   DISULFID    332    353       {ECO:0000269|PubMed:9690478}.
FT   DISULFID    455    488       {ECO:0000269|PubMed:9690478}.
FT   CROSSLNK   1168   1168       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000269|PubMed:21994939}.
FT   CROSSLNK   1171   1171       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000269|PubMed:21994939}.
FT   VARIANT     105    105       V -> L (in a renal chromophobe sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041424.
FT   VARIANT     138    138       R -> Q (in IGF1RES; has decreased IGF1R
FT                                function; dbSNP:rs121912426).
FT                                {ECO:0000269|PubMed:14657428}.
FT                                /FTId=VAR_034891.
FT   VARIANT     145    145       K -> N (in IGF1RES; has decreased IGF1R
FT                                function; dbSNP:rs121912427).
FT                                {ECO:0000269|PubMed:14657428}.
FT                                /FTId=VAR_034892.
FT   VARIANT     359    359       N -> Y (in IGF1RES; significant decrease
FT                                in IGF1-induced DNA synthesis and AKT1
FT                                phosphorylation in patient fibroblasts).
FT                                {ECO:0000269|PubMed:25040157}.
FT                                /FTId=VAR_076247.
FT   VARIANT     388    388       V -> M (in dbSNP:rs45445894).
FT                                {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_018855.
FT   VARIANT     437    437       R -> H (in dbSNP:rs34516635).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_034893.
FT   VARIANT     511    511       R -> Q (in dbSNP:rs33958176).
FT                                /FTId=VAR_034894.
FT   VARIANT     595    595       R -> H (in dbSNP:rs56248469).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041425.
FT   VARIANT     605    605       R -> H (in dbSNP:rs45553041).
FT                                {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_018856.
FT   VARIANT     739    739       R -> Q (in IGF1RES; leads to failure of
FT                                processing of the IGF1R proreceptor to
FT                                mature IGF1R; dbSNP:rs121912429).
FT                                {ECO:0000269|PubMed:15928254}.
FT                                /FTId=VAR_034895.
FT   VARIANT     808    808       H -> R (in dbSNP:rs34061581).
FT                                /FTId=VAR_034896.
FT   VARIANT     828    828       A -> T (in dbSNP:rs35224135).
FT                                /FTId=VAR_034897.
FT   VARIANT     857    857       N -> S (in dbSNP:rs45611935).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041426.
FT   VARIANT     865    865       Y -> C (in IGF1RES; significant decrease
FT                                in IGF1-induced DNA synthesis and AKT1
FT                                phosphorylation in patient fibroblasts).
FT                                {ECO:0000269|PubMed:25040157}.
FT                                /FTId=VAR_076248.
FT   VARIANT    1256   1256       R -> S (in IGF1RES; significant decrease
FT                                in IGF1-induced DNA synthesis and AKT1
FT                                phosphorylation in patient fibroblasts).
FT                                {ECO:0000269|PubMed:25040157}.
FT                                /FTId=VAR_076249.
FT   VARIANT    1337   1337       R -> C (in IGF1RES; a benign mutation or
FT                                a rare polymorphism, significant decrease
FT                                in IGF1-induced DNA synthesis;
FT                                significant increase in IGF1-induced AKT1
FT                                phosphorylation in patient fibroblasts;
FT                                dbSNP:rs141802822).
FT                                {ECO:0000269|PubMed:25040157}.
FT                                /FTId=VAR_076250.
FT   VARIANT    1338   1338       A -> T (in dbSNP:rs34102392).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041427.
FT   VARIANT    1347   1347       A -> V (in a lung squamous cell carcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041428.
FT   MUTAGEN     980    980       Y->F: Reduces tyrosine phosphorylation.
FT                                Abolishes interaction with IRS1 and SHC1.
FT                                Does not abolish interaction with PIK3R1,
FT                                nor with GRB10.
FT                                {ECO:0000269|PubMed:10454568,
FT                                ECO:0000269|PubMed:7541045}.
FT   MUTAGEN    1033   1033       K->A: Kinase inactive. Abolishes tyrosine
FT                                phosphorylation and abolishes interaction
FT                                with IRS1, SHC1 and PIK3R1.
FT                                {ECO:0000269|PubMed:7541045}.
FT   MUTAGEN    1280   1280       Y->F: No effect on GRB10-binding.
FT                                {ECO:0000269|PubMed:10454568}.
FT   MUTAGEN    1281   1281       Y->F: No effect on GRB10-binding.
FT                                {ECO:0000269|PubMed:10454568}.
FT   MUTAGEN    1346   1346       Y->F: Loss of GRB10-binding.
FT                                {ECO:0000269|PubMed:10454568}.
FT   CONFLICT    928    929       TG -> R (in Ref. 3; BAG11657).
FT                                {ECO:0000305}.
FT   STRAND       37     41       {ECO:0000244|PDB:1IGR}.
FT   HELIX        43     49       {ECO:0000244|PDB:1IGR}.
FT   STRAND       53     57       {ECO:0000244|PDB:1IGR}.
FT   STRAND       59     65       {ECO:0000244|PDB:1IGR}.
FT   STRAND       68     70       {ECO:0000244|PDB:1IGR}.
FT   STRAND       80     83       {ECO:0000244|PDB:1IGR}.
FT   STRAND       85     92       {ECO:0000244|PDB:1IGR}.
FT   HELIX        96     98       {ECO:0000244|PDB:1IGR}.
FT   STRAND      115    121       {ECO:0000244|PDB:1IGR}.
FT   STRAND      138    144       {ECO:0000244|PDB:1IGR}.
FT   HELIX       157    160       {ECO:0000244|PDB:1IGR}.
FT   HELIX       164    166       {ECO:0000244|PDB:1IGR}.
FT   STRAND      168    171       {ECO:0000244|PDB:1IGR}.
FT   HELIX       175    178       {ECO:0000244|PDB:1IGR}.
FT   TURN        183    188       {ECO:0000244|PDB:1IGR}.
FT   STRAND      194    199       {ECO:0000244|PDB:1IGR}.
FT   STRAND      201    203       {ECO:0000244|PDB:1IGR}.
FT   STRAND      205    209       {ECO:0000244|PDB:1IGR}.
FT   HELIX       217    219       {ECO:0000244|PDB:1IGR}.
FT   STRAND      235    241       {ECO:0000244|PDB:1IGR}.
FT   STRAND      247    255       {ECO:0000244|PDB:1IGR}.
FT   STRAND      257    263       {ECO:0000244|PDB:1IGR}.
FT   STRAND      269    271       {ECO:0000244|PDB:1IGR}.
FT   TURN        272    274       {ECO:0000244|PDB:1IGR}.
FT   STRAND      275    277       {ECO:0000244|PDB:1IGR}.
FT   HELIX       279    283       {ECO:0000244|PDB:1IGR}.
FT   STRAND      297    299       {ECO:0000244|PDB:1IGR}.
FT   STRAND      302    306       {ECO:0000244|PDB:1IGR}.
FT   STRAND      311    315       {ECO:0000244|PDB:1IGR}.
FT   STRAND      321    323       {ECO:0000244|PDB:1IGR}.
FT   STRAND      325    327       {ECO:0000244|PDB:1IGR}.
FT   STRAND      331    341       {ECO:0000244|PDB:1IGR}.
FT   HELIX       345    347       {ECO:0000244|PDB:1IGR}.
FT   TURN        349    352       {ECO:0000244|PDB:1IGR}.
FT   STRAND      354    362       {ECO:0000244|PDB:1IGR}.
FT   HELIX       375    378       {ECO:0000244|PDB:1IGR}.
FT   STRAND      383    386       {ECO:0000244|PDB:1IGR}.
FT   STRAND      388    392       {ECO:0000244|PDB:1IGR}.
FT   TURN        415    417       {ECO:0000244|PDB:1IGR}.
FT   STRAND      418    423       {ECO:0000244|PDB:1IGR}.
FT   TURN        434    436       {ECO:0000244|PDB:1IGR}.
FT   STRAND      440    443       {ECO:0000244|PDB:1IGR}.
FT   STRAND      445    451       {ECO:0000244|PDB:1IGR}.
FT   HELIX       456    466       {ECO:0000244|PDB:1IGR}.
FT   STRAND      474    477       {ECO:0000244|PDB:1IGR}.
FT   TURN        479    481       {ECO:0000244|PDB:1IGR}.
FT   HELIX       724    730       {ECO:0000244|PDB:4XSS}.
FT   STRAND      980    982       {ECO:0000244|PDB:1P4O}.
FT   HELIX       983    985       {ECO:0000244|PDB:2ZM3}.
FT   TURN        990    992       {ECO:0000244|PDB:2OJ9}.
FT   HELIX       996    998       {ECO:0000244|PDB:1P4O}.
FT   STRAND      999   1007       {ECO:0000244|PDB:1P4O}.
FT   STRAND     1009   1022       {ECO:0000244|PDB:1P4O}.
FT   STRAND     1025   1034       {ECO:0000244|PDB:1P4O}.
FT   STRAND     1037   1039       {ECO:0000244|PDB:3F5P}.
FT   HELIX      1041   1053       {ECO:0000244|PDB:1P4O}.
FT   HELIX      1054   1056       {ECO:0000244|PDB:1P4O}.
FT   STRAND     1065   1069       {ECO:0000244|PDB:1P4O}.
FT   STRAND     1071   1074       {ECO:0000244|PDB:1P4O}.
FT   STRAND     1076   1080       {ECO:0000244|PDB:1P4O}.
FT   HELIX      1087   1100       {ECO:0000244|PDB:1P4O}.
FT   HELIX      1109   1128       {ECO:0000244|PDB:1P4O}.
FT   HELIX      1138   1140       {ECO:0000244|PDB:1P4O}.
FT   STRAND     1141   1143       {ECO:0000244|PDB:1P4O}.
FT   STRAND     1149   1151       {ECO:0000244|PDB:1P4O}.
FT   HELIX      1155   1157       {ECO:0000244|PDB:3D94}.
FT   HELIX      1159   1164       {ECO:0000244|PDB:1P4O}.
FT   TURN       1165   1167       {ECO:0000244|PDB:3LVP}.
FT   HELIX      1168   1170       {ECO:0000244|PDB:1P4O}.
FT   STRAND     1171   1174       {ECO:0000244|PDB:1P4O}.
FT   HELIX      1176   1178       {ECO:0000244|PDB:1P4O}.
FT   HELIX      1181   1186       {ECO:0000244|PDB:1P4O}.
FT   HELIX      1191   1207       {ECO:0000244|PDB:1P4O}.
FT   TURN       1212   1215       {ECO:0000244|PDB:1P4O}.
FT   HELIX      1218   1226       {ECO:0000244|PDB:1P4O}.
FT   HELIX      1239   1248       {ECO:0000244|PDB:1P4O}.
FT   HELIX      1253   1255       {ECO:0000244|PDB:1P4O}.
FT   HELIX      1259   1266       {ECO:0000244|PDB:1P4O}.
FT   HELIX      1267   1269       {ECO:0000244|PDB:1P4O}.
FT   HELIX      1274   1277       {ECO:0000244|PDB:1P4O}.
FT   TURN       1279   1281       {ECO:0000244|PDB:3O23}.
FT   TURN       1283   1285       {ECO:0000244|PDB:3LVP}.
FT   STRAND     1286   1288       {ECO:0000244|PDB:1P4O}.
SQ   SEQUENCE   1367 AA;  154793 MW;  AE8A735F87F745C8 CRC64;
     MKSGSGGGSP TSLWGLLFLS AALSLWPTSG EICGPGIDIR NDYQQLKRLE NCTVIEGYLH
     ILLISKAEDY RSYRFPKLTV ITEYLLLFRV AGLESLGDLF PNLTVIRGWK LFYNYALVIF
     EMTNLKDIGL YNLRNITRGA IRIEKNADLC YLSTVDWSLI LDAVSNNYIV GNKPPKECGD
     LCPGTMEEKP MCEKTTINNE YNYRCWTTNR CQKMCPSTCG KRACTENNEC CHPECLGSCS
     APDNDTACVA CRHYYYAGVC VPACPPNTYR FEGWRCVDRD FCANILSAES SDSEGFVIHD
     GECMQECPSG FIRNGSQSMY CIPCEGPCPK VCEEEKKTKT IDSVTSAQML QGCTIFKGNL
     LINIRRGNNI ASELENFMGL IEVVTGYVKI RHSHALVSLS FLKNLRLILG EEQLEGNYSF
     YVLDNQNLQQ LWDWDHRNLT IKAGKMYFAF NPKLCVSEIY RMEEVTGTKG RQSKGDINTR
     NNGERASCES DVLHFTSTTT SKNRIIITWH RYRPPDYRDL ISFTVYYKEA PFKNVTEYDG
     QDACGSNSWN MVDVDLPPNK DVEPGILLHG LKPWTQYAVY VKAVTLTMVE NDHIRGAKSE
     ILYIRTNASV PSIPLDVLSA SNSSSQLIVK WNPPSLPNGN LSYYIVRWQR QPQDGYLYRH
     NYCSKDKIPI RKYADGTIDI EEVTENPKTE VCGGEKGPCC ACPKTEAEKQ AEKEEAEYRK
     VFENFLHNSI FVPRPERKRR DVMQVANTTM SSRSRNTTAA DTYNITDPEE LETEYPFFES
     RVDNKERTVI SNLRPFTLYR IDIHSCNHEA EKLGCSASNF VFARTMPAEG ADDIPGPVTW
     EPRPENSIFL KWPEPENPNG LILMYEIKYG SQVEDQRECV SRQEYRKYGG AKLNRLNPGN
     YTARIQATSL SGNGSWTDPV FFYVQAKTGY ENFIHLIIAL PVAVLLIVGG LVIMLYVFHR
     KRNNSRLGNG VLYASVNPEY FSAADVYVPD EWEVAREKIT MSRELGQGSF GMVYEGVAKG
     VVKDEPETRV AIKTVNEAAS MRERIEFLNE ASVMKEFNCH HVVRLLGVVS QGQPTLVIME
     LMTRGDLKSY LRSLRPEMEN NPVLAPPSLS KMIQMAGEIA DGMAYLNANK FVHRDLAARN
     CMVAEDFTVK IGDFGMTRDI YETDYYRKGG KGLLPVRWMS PESLKDGVFT TYSDVWSFGV
     VLWEIATLAE QPYQGLSNEQ VLRFVMEGGL LDKPDNCPDM LFELMRMCWQ YNPKMRPSFL
     EIISSIKEEM EPGFREVSFY YSEENKLPEP EELDLEPENM ESVPLDPSAS SSSLPLPDRH
     SGHKAENGPG PGVLVLRASF DERQPYAHMN GGRKNERALP LPQSSTC
//
